HC Wainwright & Co. Initiates Coverage On Pelthos Therapeutics with Buy Rating, Announces Price Target of $60
Benzinga Newsdesk 11 months ago
NewsPrice TargetInitiationAnalyst Ratings
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
HC Wainwright & Co. analyst Brandon Folkes initiates coverage on Pelthos Therapeutics (AMEX:PTHS) with a Buy rating and announces Price Target of $60.
HC Wainwright & Co. analyst Brandon Folkes initiates coverage on Pelthos Therapeutics (AMEX:PTHS) with a Buy rating and announces Price Target of $60.
